Statins Are Associated With Reduced Mortality in Multiple Myeloma
The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) have activity in one of the pathways influenced by nitrogen-containing bisphosphonates, which are associated with improved survival in multiple myeloma (MM). As a result, a study published online in the Journal of Clinical Oncology (19 September 2016) was performed to evaluate the association between statin use and mortality in a large cohort of patients with MM.
For the study, patients were identified from the Veterans Administration Central Cancer Registry who were diagnosed with MM between 1999 and 2013. The authors defined statin use as the presence of any prescription for a statin within 3 months before or any time after MM diagnosis. The authors identified a cohort of 4,957 patients, of whom 2,294 received statin therapy. Results showed that statin use was associated with a 21% decrease in all-cause mortality (P < .001) as well as a 24% decrease in MM-specific mortality (P < .001). This association remained significant across all sensitivity analyses. In addition to reductions in mortality, statin use was associated with a 31% decreased risk of developing a skeletal-related event.
The authors stated that the findings suggest a potential role for statin therapy in patients with MM and that the putative benefit of statin therapy in MM should be corroborated in prospective studies.